Telesis Bio, Inc. (TBIO) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Telesis Bio, Inc. faces significant business risk due to non-compliance with Nasdaq’s Minimum Bid Price and Stockholders’ Equity Requirements. Despite a reverse stock split aimed at addressing the bid price issue, there’s no certainty it will restore compliance or prevent the adverse effects of potential delisting. Additionally, the company must submit a Compliance Plan to address its shortfall in stockholder equity, with the risk of delisting looming if the plan is rejected. Delisting could severely impact Telesis Bio’s market presence, stock liquidity, and capital-raising efforts, jeopardizing its financial stability.
Overall, Wall Street has a Moderate Buy consensus rating on TBIO stock based on 1 Buy.
To learn more about Telesis Bio, Inc.’s risk factors, click here.
